FMP
Phathom Pharmaceuticals, Inc.
PHAT
NASDAQ
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
7.45 USD
-0.37 (-4.97%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Ms. Terrie J. Curran
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
CIK
0001783183
ISIN
US71722W1071
CUSIP
71722W107
Address
100 Campus Drive
Phone
877 742 8466
Country
US
Employee
452
IPO Date
Oct 25, 2019
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
PHAT Financial Summary
CIK
0001783183
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
71722W107
ISIN
US71722W1071
Country
US
Price
7.45
Beta
0.72
Volume Avg.
1.27M
Market Cap
509.41M
Shares
-
52-Week
6.065-19.71
DCF
4.77
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.3
P/B
-
Website
https://www.phathompharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest PHAT News
It looks like there's no news available.
